Familiarize yourself with the most up to date strategies in managing advanced-stage Parkinson’s Disease! This adaptive activity provides a tailored learning experience with customized educational materials targeted to your specific needs. Learn ways to level-up your evaluation skills to better recognize unmet treatment needs, symptom burden, and progression to advanced-staged Parkinson’s disease as well as review the latest clinical data on available and upcoming treatments along with strategies to incorporate patients’ preferences and goals into personalized treatment decision-making. Test your knowledge, receive real-time feedback, and create your own unique experience available as a downloadable resource upon completion. Through this educational activity, you have the opportunity to earn a maximum of 2.0 CE credits in total. To achieve this, you can complete the PRIME activity (answer the questions and read the text-based explanations) to earn 1.0 CE credit. Additionally, if you choose to engage with the optional accredited articles, you can earn up to 1.0 additional CE credit. If you decide not to engage with these articles, you can still claim partial credit based on your level of participation. Total Possible Credits: 2.0 CE Credits from completing PRIME activity: 1.0 CE Additional credits from reading optional accredited articles: 1.0 CE
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/aligning-clinical-practices-latest-evidence-advanced-parkinsons-disease
- Start Date: 2024-04-30 05:00:00
- End Date: 2024-04-30 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 2.0 hours
AMA PRA Category 1 Credit™️: 2.0 hours
Nursing: 2.0 hours
Pharmacy: 2.0 hours - Commercial Support: Source: AbbVie (Any division) - Amount: 53375.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all